Banque Transatlantique SA Invests $2.86 Million in Moderna, Inc. (NASDAQ:MRNA)

Banque Transatlantique SA purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 69,708 shares of the company’s stock, valued at approximately $2,858,000.

Several other large investors have also made changes to their positions in MRNA. Norges Bank bought a new stake in Moderna in the fourth quarter worth approximately $163,833,000. FMR LLC boosted its holdings in Moderna by 7.4% in the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock worth $776,075,000 after purchasing an additional 1,282,469 shares in the last quarter. Pictet Asset Management Holding SA boosted its holdings in Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock worth $73,447,000 after purchasing an additional 1,113,455 shares in the last quarter. Invesco Ltd. increased its position in Moderna by 24.3% during the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company’s stock worth $208,169,000 after buying an additional 979,858 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Moderna by 225.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company’s stock valued at $42,027,000 after buying an additional 700,458 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 2.1 %

Shares of NASDAQ MRNA opened at $27.61 on Friday. The firm has a market capitalization of $10.67 billion, a price-to-earnings ratio of -2.98 and a beta of 1.99. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The business has a fifty day simple moving average of $29.52 and a 200 day simple moving average of $37.46.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company had revenue of $108.00 million during the quarter, compared to analysts’ expectations of $130.35 million. During the same quarter in the prior year, the company posted ($3.07) EPS. The business’s revenue was down 35.3% on a year-over-year basis. On average, research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on MRNA shares. Morgan Stanley lowered their price objective on Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 9th. UBS Group dropped their price target on shares of Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday. Berenberg Bank upped their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Thursday, April 17th. Finally, Bank of America decreased their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.